InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Inks Exclusive License Agreement with Medspray Pharma BV
November 21, 2023
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an exclusive licensing agreement with medical tech manufacturer Medspray Pharma BV. The agreement is for Medspray’s a proprietary patented soft-mist nasal spray technology, the delivery mechanism that will be used in Silo’s intranasal therapeutic drug […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Closing of Oversubscribed Private Placement
November 20, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced that it has closed its private placement of unsecured convertible notes for aggregate gross proceeds of AUD$3,215,000, which represents an oversubscription of AUD$215,000 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host CYB003 Topline Depression Study Review, Briefing
November 20, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that it will discuss its topline phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive […]
InvestorNewsBreaks — Laredo Oil Inc. (LRDC) Releases Results from Drilling Conducted through Texakoma Exploration and Production Agreement
November 17, 2023
Laredo Oil (OTC: LRDC), an oil exploration and production company, is reporting on results of its drilling project in Montana. According to the announcement, drilling has encountered free oil and drill cutting oil shows from the main target zone in the first of two exploratory wells. The drilling is part of the agreement between Laredo […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release, Discuss Topline Safety and Efficacy Data for MDD Study during Upcoming Event
November 16, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be hosting a research and development briefing on Nov. 30, 2023, at 10 a.m. ET in New York City. During the event, the company will release topline phase 2 safety and efficacy […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Poster Presentation at Neuroscience 2023, Closing of Underwritten Offering and Q2 Results, Recent Business Highlights
November 15, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023. The event, hosted by the Society for Neuroscience (“SFN”), is taking place Nov. 11-15, 2022, in Washington, D.C. “It is always exciting […]
InvestorNewsBreaks – Gratomic Inc. (TSX.V: GRAT) (OTCQX: CBULF) (FSE: CB82) Reports On Commercial Commissioning Phase at Aukam Graphite Mine
November 15, 2023
Gratomic (TSX.V: GRAT) (OTCQX: CBULF) (FSE: CB82), a multinational company with projects in Namibia, Brazil and Canada, has released an update on its wholly owned Aukam graphite mine and processing plant in Namibia. According to the report, since the company began the commercial commissioning phase in June, Gratomic has processed 80 tonnes of material through […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces up to US$64M Offering
November 10, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options. The company today announced a firm commitment underwritten offering of 66,666,667 units of CYBN to one of its largest existing institutional shareholders and new institutional investors at a price […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Initiate Dose-Ranging Study, Positioning for Early Start of Phase 1 Clinical Trial of SPC-15
November 8, 2023
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (“PTSD”). The six- to eight-week non-good laboratory practice (“GLP”) study will identify the maximum tolerated intranasal dose […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Announces Participation at Upcoming Milken Institute Future of Health Summit
November 3, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be represented at the 2023 Milken Institute Future of Health Summit. According to the announcement, Cybin CEO Doug Drysdale is slated to participate on a panel about innovations in mental health care; […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Anticipates Gross Proceeds of AUD$3M on Private Placement
November 2, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has announced a private placement of unsecured convertible notes. The placement is for of up to AUD$3 million and includes the ability to accept oversubscriptions of up to […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Breakthrough Results of Phase 2 Study of MDD Treatment
November 2, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is reporting on interim results from its phase 2 study of CYB003, the company’s proprietary deuterated psilocybin analog, designed to treat major depressive disorder (“MDD”). According to the announcement, the results demonstrate […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones
November 1, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released a clinical-stage program update and noted upcoming milestones for its development pipeline. Those milestones for CYB003, the company’s deuterated psilocybin analog program, include the completion of phase 2 topline safety and […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Files Prospectus Supplement, Closes Share Subscription Agreements
October 31, 2023
Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has filed a shelf prospectus supplement to its Final Short Form Base Shelf Prospectus for the province of Québec and its Amended and […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder
October 31, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options. The company today announced phase 2 interim results for CYB003, its proprietary deuterated psilocybin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks […]
HUB Cyber Security Signs an LOI to Acquire a Strategic Product Developer Cyber Security Company
October 31, 2023
TEL AVIV, Israel, Oct. 31, 2023 (GLOBE NEWSWIRE) — via IBN — HUB Cyber Security Ltd. (Nasdaq: HUBC), a developer of Confidential Computing cybersecurity solutions and services (“HUB” or the “Company”), announces a strategic alliance LOI with a company with cutting-edge technology in the automation of cyber risk detection and responses. The LOI contemplates that both […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent
October 26, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the European Patent Office (“EP”) has granted a patent protecting Cybin’s proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (“DMT”) programs. “Maintaining a secure intellectual property […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Reports on Company Progress in Q4 2023 Update
October 26, 2023
Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has released a fourth-quarter 2023 company update. According to the update, the company has worked to simplify its business model, streamline workflow and […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program
October 25, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has been granted two patents by the United States Patent and Trademark Office; the patents offer protection for the company’s deuterated N, N-dimethyltryptamine (“DMT”) program, including deuterated analogs of DMT related to composition […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
October 23, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) together with Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF) announced the completion of the previously disclosed acquisition by Cybin of Small Pharma by way of a plan of arrangement under the Business Corporations Act (British Columbia), and pursuant to the terms of an arrangement agreement dated Aug. 28, 2023, […]
InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthen Position in Alternative Mental-Health Treatments Sector
October 18, 2023
Lucy Scientific Discovery (NASDAQ: LSDI), a pioneer in alternative mental-health treatments, is working to provide ingredients for effective mental-health treatment and therapies, including psilocybin and MDMA. According to a recent article spotlighting LSDI, the company is “well positioned” to support the mental-health space as it continues to grow. The article noted that mental-health issues are […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results of Preclinical Study to Advance SPU-21
October 16, 2023
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 works to selectively target inflamed synovial tissue to inhibit […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting
October 13, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the results of its annual and special meeting of shareholders, which was held Oct. 12, 2023. According to the announcement, 66 shareholders attended the meeting, either in person or by […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD$175,000 Private Placement
October 12, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has closed its previously announced private placement of unsecured convertible debentures to Jason Carroll, Tryp’s newly appointed CEO. The private placement was for gross proceeds of AUD$175,000. Tryp […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Initiates Human Factor Study of Its Targeted Prophylactic Treatment SPC-15
October 11, 2023
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (“PTSD”). According to the announcement, the study will evaluate the human factor interface and usability of […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Starts Trading on the AQSE Growth Market
October 10, 2023
Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has completed its admission to the Access segment of the AQSE Growth Market; the company begins trading on today at market open. According […]
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit
October 6, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be presenting at the Neuropsychiatric Drug Development Summit, slated for Oct. 11–12, 2023, in Boston. Cybin’s abstract, titled “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential,” […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) Common Shares Begin Listing on CSE
October 6, 2023
Mydecine Innovations (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has received approval to list its common shares on the Canadian Securities Exchange (“CSE”). The company therefore submitted a request to the NEO […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 4, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has announced that its CEO Doug Drysdale will present at the Jefferies Inaugural Biotech CNS/Neuro Summit. The event is slated to take place in New York City on Oct. 11-12, 2023, with […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Wraps Up Phase 2 Study Dosing for Final Cohort
October 3, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has completed dosing of the final cohort for its phase 2 CYB003 study. According to the announcement, the company anticipates reporting topline efficacy data later this year; Cybin is also looking forward to […]
InvestorNewsBreaks — Quess GTS, Proviniti Partner to Provide Key ServiceNow Solutions for Enterprise Customers
September 28, 2023
Quess GTS, a leading provider of digital transformation, cloud optimization, cyber, automation, platform modernization and managed services, has entered into an agreement with Proviniti, a global consulting services firm that specializes in ServiceNow domain-led solutions. The agreement is designed to deploy ServiceNow industry solutions across targeted vertical industries globally. The strategic partnership will drive ServiceNow options […]
Quess GTS and Proviniti Enter into Strategic Partnership to Drive ServiceNow solutions for Enterprise Customers
September 28, 2023
NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) — via IBN — Quess GTS, a leading provider of Digital Transformation, Cloud Optimization, Cyber, Automation, Platform Modernization and Managed Services and Proviniti, a global consulting services firm with specialized focus in ServiceNow domain-led solutions, today announced a strategic partnership to deploy ServiceNow industry solutions across targeted vertical industries globally. Pinaki […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Expects UK Dual Listing Admission Next Month
September 28, 2023
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is expecting admission of its common shares to begin trading on the Access Segment of the AQSE (“AQSE”) Growth Market in the United […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Positive Top-Line Data Gathered from Small Pharma Study
September 27, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is giving kudos to Small Pharma Inc., a biotechnology company focused on short-duration, psychedelic-assisted therapies for mental-health conditions. Small Pharma is reporting positive safety, tolerability and efficacy data gathered from its phase Ib […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners with Fluence in Preparation to Advance CYB003 Toward Pivotal Studies
September 26, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced an agreement with Fluence, a leading continuing education organization in psychedelic therapy, to support the streamlining and scaling of Cybin’s EMBARK facilitator training program in preparation […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Cantor Global Healthcare Conference
September 25, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options. The company today announced that its CEO Doug Drysdale and the CEO of Small Pharma Inc., George Tziras, will participate in a panel discussion at the Cantor Global Healthcare Conference taking […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting
September 22, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is making plans for its annual shareholder meeting. The company announced that it has scheduled its 2023 Annual and Special Meeting of Shareholders; the meeting will be held virtually on Oct. 12, 2023, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Enrollment in Phase 2 CYB003 Study
September 21, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company announced that it has completed enrollment in its phase 2 study of CYB003, a proprietary deuterated psilocybin analog program being developed for the potential treatment of major depressive […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive SPC-15 Data, Plans to File Pre-IND Application
September 20, 2023
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is partnering with Kymanox as the company prepares a pre-Investigational New Drug (“IND”) package and meeting request with the United States Food and Drug Administration (“FDA”). Silo made the decision to move forward after receiving positive SPC-15 preclinical data. […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Begin Feasibility Study of Proprietary Novel Intranasal Formulation for PTSD
September 12, 2023
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has begun an exploratory feasibility study assessing a selected delivery mechanism for its intranasal therapeutic drug SPC-15 in the treatment of post-traumatic stress syndrome (“PTSD”). The company is partnering with a developer and manufacturer of innovative drug-delivery systems and […]